MASTELAD VIAL Driada Medical
| Features | |
| Also known as | D-Trp6-LHRH |
| Blood pressure | Generally has no significant effect on blood pressure |
| Chemical name | Triptorelin acetate |
| Dosage (medical) | Typically 3.75 mg every 4 weeks by intramuscular injection for prostate cancer treatment |
| Dosage (sports) | Not applicable, as it is not typically used for performance enhancement |
| Effects | Decreases testosterone in men and estrogen in women |
| Formula | C64H82N18O13 (for triptorelin), C2H4O2 (for acetate) |
| Half-life | Approximately 3 hours (initial), 3-6 weeks after depot formulations |
| Hepatotoxicity | No significant hepatotoxic effects reported |
| Lab Test | Blood levels of gonadotropins and sex steroids can be monitored |
| Main action | Suppresses pituitary gonadotropin secretion |
| Raw Material | Drostanolone Propionate |
| Side effects | Hot flashes, mood swings, decreased libido, fatigue, headache, erectile dysfunction |
| Storage conditions | Store at controlled room temperature, protect from light |
| Substance class | Gonadotropin-releasing hormone agonist (GnRH agonist) |
| Trade name | Decapeptyl, Trelstar, Gonapeptyl, among others |
| Use in sports | Not commonly used in sports |
| Water Retention | No significant effect on water retention |
| Manufacturer | DRIADA |
| Packing | 10 ml vial (100 mg/ml) |